Congress Already Preparing For User Fee Bills
Executive Summary
Multiple congressional offices attended a briefing on GDUFA III with FDA and industry officials, suggesting plans for the must-pass bill already are in the works.
You may also be interested in...
US FDA Aims To Speed Communications On Cell And Gene Therapy Issues With Q&A Guidance
Advocates also call for reauthorization negotiations to be open to the public during meeting on the PDUFA VII commitment letter.
US GDUFA III Talks In Final Stages, Agreement Nearly Complete
Final commitment letter preparations now under way as revenue issues are resolved.
FDA Considers Incorporating Patient Input In Generic Drug Assessments
The popular patient-focused drug development model for new drugs might not fit for generics, in part because the affected patient groups would be much larger.